Literature DB >> 12847520

SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses.

Yoh-ichi Seki1, Hiromasa Inoue, Naoko Nagata, Katsuhiko Hayashi, Satoru Fukuyama, Koichiro Matsumoto, Okiru Komine, Shinjiro Hamano, Kunisuke Himeno, Kyoko Inagaki-Ohara, Nicholas Cacalano, Anne O'Garra, Tadahilo Oshida, Hirohisa Saito, James A Johnston, Akihiko Yoshimura, Masato Kubo.   

Abstract

Members of the suppressor of cytokine signaling (SOCS) family are involved in the pathogenesis of many inflammatory diseases. SOCS-3 is predominantly expressed in T-helper type 2 (T(H)2) cells, but its role in T(H)2-related allergic diseases remains to be investigated. In this study we provide a strong correlation between SOCS-3 expression and the pathology of asthma and atopic dermatitis, as well as serum IgE levels in allergic human patients. SOCS-3 transgenic mice showed increased T(H)2 responses and multiple pathological features characteristic of asthma in an airway hypersensitivity model system. In contrast, dominant-negative mutant SOCS-3 transgenic mice, as well as mice with a heterozygous deletion of Socs3, had decreased T(H)2 development. These data indicate that SOCS-3 has an important role in regulating the onset and maintenance of T(H)2-mediated allergic immune disease, and suggest that SOCS-3 may be a new therapeutic target for the development of antiallergic drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12847520     DOI: 10.1038/nm896

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  119 in total

1.  Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus.

Authors:  Yuan Fang; Thomas Rowe; Alberto J Leon; David Banner; Ali Danesh; Luoling Xu; Longsi Ran; Steven E Bosinger; Yi Guan; Honglin Chen; Cheryl C Cameron; Mark J Cameron; David J Kelvin
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  Asthma: new developments in cytokine regulation.

Authors:  R J Boyton; D M Altmann
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

Review 3.  Regulation of CD4+ T-cell polarization by suppressor of cytokine signalling proteins.

Authors:  Camille A Knosp; James A Johnston
Journal:  Immunology       Date:  2012-02       Impact factor: 7.397

4.  Genetic correlation of SOCS3 polymorphisms with infantile asthma: an evidence based on a case-control study.

Authors:  Ying Fang; Xiaoxia Ren; Zhanwei Feng
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 5.  Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas.

Authors:  Tracey J Mitchell; Susan John
Journal:  Immunology       Date:  2005-03       Impact factor: 7.397

Review 6.  Suppressors of cytokine signaling in health and disease.

Authors:  Jane C Tan; Ralph Rabkin
Journal:  Pediatr Nephrol       Date:  2005-02-19       Impact factor: 3.714

Review 7.  Negative regulation of cytokine signaling.

Authors:  Akihiko Yoshimura
Journal:  Clin Rev Allergy Immunol       Date:  2005-06       Impact factor: 8.667

8.  Elevated expression and genetic association links the SOCS3 gene to atopic dermatitis.

Authors:  E Ekelund; A Saaf; M Tengvall-Linder; E Melen; J Link; J Barker; N J Reynolds; S J Meggitt; J Kere; C-F Wahlgren; G Pershagen; M Wickman; M Nordenskjold; I Kockum; M Bradley
Journal:  Am J Hum Genet       Date:  2006-04-14       Impact factor: 11.025

9.  Expression of human pim family genes is selectively up-regulated by cytokines promoting T helper type 1, but not T helper type 2, cell differentiation.

Authors:  Teija L T Aho; Riikka J Lund; Emmi K Ylikoski; Sampsa Matikainen; Riitta Lahesmaa; Päivi J Koskinen
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

10.  Myeloid depletion of SOCS3 enhances LPS-induced acute lung injury through CCAAT/enhancer binding protein δ pathway.

Authors:  Chunguang Yan; Peter A Ward; Ximo Wang; Hongwei Gao
Journal:  FASEB J       Date:  2013-04-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.